|
|
Article: OTHER NEWS TO NOTE.
- Article from:
- BIOWORLD Today
- Article date:
- August 21, 2001
CopyrightCOPYRIGHT 2001 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Amsterdam Molecular Therapeutics B.V., of Amsterdam, the Netherlands, signed an exclusive sublicense and research agreement with Xenon Genetics Inc., of Vancouver, British Columbia, in a deal that gives AMT access to technology and intellectual property relating to lipoprotein lipase LPL. Under the terms of the partnership, AMT and Xenon will join forces in a preclinical research program for LPL gene therapy. AMT will be responsible for further development and commercialization.
Anadys Pharmaceuticals Inc., of San Diego, said it developed an integrated chemoinformatics platform - a software suite - that includes elements to organize and track its chemical ...